Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Aehr Test Systems is winning repeat AI business, with a $22M follow-on order from a major AI customer for its FOX-XP wafer-level burn-in systems that adds chip capacity over the next six months. Jefferies initiated coverage with a Buy and a $175 target, calling it undervalued given its AI, silicon photonics and networking exposure. After three straight weeks of selling off the highs, volume is coming in while the stock holds its 200-day EMA, setting up a curl higher. x.com 

Aehr Test Systems' addressable market looks tiny compared with 200 other AI companies, making it unattractive. x.com 

Aehr Test Systems has become a key picks-and-shovels supplier to the AI chip boom, with its Sonoma platform the go-to system for reliability testing of high-power AI processors. On April 16, 2026, it announced a $41M follow-on order, its largest ever, from an unnamed hyperscale AI chip leader for custom AI ASIC testing, with revenue from fiscal 2027. Backlog doubled to $38.7M, second-half FY26 bookings exceed $92M, and FY26 should hit the high end of $45-50M guidance. x.com 

Aehr Test Systems' selloff reflects confusion, not fundamentals: traders dumped the stock after finance sites wrongly listed its earnings for October 6, while a strong order announcement got ignored. Its lead hyperscaler test customer, which already uses Sonoma to test one AI processor in high-volume production, ordered more equipment for a second, newer processor expected to ramp in 2027. x.com 

Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.com 

Aehr Test Systems had a great quarterly call, and the stock now sits at a key pivot. x.com 

Aehr Test Systems' AI wafer-level burn-in business is scaling, with a $22M follow-on order from its lead AI processor customer to expand capacity for high-volume production. That customer is already planning more capacity, and Aehr is expanding talks with other hyperscalers. The stock reached fresh all-time highs, and its recent strength looks like institutional accumulation. x.com  x.com  x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Reported advanced-testing price increases could boost AI chip-testing suppliers. Dan Nystedt cites media reports of prices set to rise 10-30% as supply falls far short of demand. ASE Technology, FormFactor and Cohu have explosive earnings-growth estimates and some of the strongest technical charts with relative strength; AI chip testing still has good upside potential. x.com